Improving Patients' Adherence to Their Chronic Treatments by Implementing a Simple, Standardized and Redundant Message Delivered by Healthcare Professionals.
NCT ID: NCT06748118
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
1210 participants
INTERVENTIONAL
2025-02-28
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For patients, their participation by filling in the therapeutic adherence self-questionnaire will enable them to become active players in the management of their treatment.
If the results of our study prove positive, this will lead to a new, optimized organization of patient care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention period
Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.
During this period, the message will be delivered to the patient by each of the healthcare professionals involved in his or her hospital care. It will be formalized by a checklist that will enable them to reformulate the 3 points defined as key elements of therapeutic adherence. Each healthcare professional is free to deliver this message at any time during their consultation/interview with the patient. They will be asked to note the date and tick off each point on the checklist.
The intervention period will take place after the control and wash-out periods, and after healthcare professionals have been trained in the intervention.
Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.
This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
Control period
The control period is the period before healthcare professionals are trained in the intervention. Patients included during this period will not receive the simple, standardized and redundant message.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action for therapeutic adherence.
This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake. The research does not anticipate any change in the patient's medical prescriptions.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliated to the French social security system
* Followed in hospital for a chronic pathology within a formalized care pathway
* Having signed a consent form to participate in the study.
Exclusion Criteria
* Patients under guardianship.
* Pregnant or breast-feeding patients.
* Patients taking part in research on compliance
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, France
OTHER_GOV
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brigitte SABATIER, Dr
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Angers
Angers, France, France
CH d'Antibes
Antibes, France, France
Hôpital Corentin Celton
Issy-les-Moulineaux, France, France
Hôpital de la Conception
Marseille, France, France
Hôpital La Timone
Marseille, France, France
CHU de Nantes
Nantes, France, France
Hôpital européen Georges-Pompidou
Paris, France, France
Hôpital Bicêtre
Paris, France, France
CHU de Toulouse
Toulouse, France, France
CHU de Tours
Tours, France, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Laurence SPIESSER-ROBELET, Dr
Role: primary
Benjamin VERRIERE, Dr
Role: primary
Yann ORVEN, Dr
Role: primary
Florian CORREARD, Dr
Role: primary
Guillaume HACHE, Dr
Role: primary
Jean-François HUON, Dr
Role: primary
Brigitte SABATIER, Dr
Role: primary
Marie-Camille CHAUMAIS, Dr
Role: primary
Philippe CESTAC, Dr
Role: primary
Laura FOUCAULT-FRUCHARD, Dr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PREPS-22-0004
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
DR-2024-271
Identifier Type: OTHER
Identifier Source: secondary_id
2024-A00701-46
Identifier Type: OTHER
Identifier Source: secondary_id
APHP230810
Identifier Type: -
Identifier Source: org_study_id